Stocks of Nektar Therapeutics (NASDAQ:NKTR) traded higher last session on Wall Street, up 22.48% to $1.58.
NKTR stock price is now 89.32% away from the 50-day moving average and 148.64% away from the 200-day moving average. The market capitalization of the company currently stands at $290.12M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
, while ‘Jefferies’ rates the stock as ‘Hold’
In other news, ROBIN HOWARD W, President & CEO sold 20,033 shares of the company’s stock on Feb 20 ’24. The stock was sold for $13,622 at an average price of $0.68. Upon completion of the transaction, the President & CEO now directly owns 879,889 shares in the company, valued at $1.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 20 ’24, Chief R&D Officer Zalevsky Jonathan sold 9,014 shares of the business’s stock. A total of $6,130 was realized by selling the stock at an average price of $0.68. This leaves the insider owning 265,025 shares of the company worth $0.42 million. A total of 3.09% of the company’s stock is owned by insiders.
During the past 12 months, Nektar Therapeutics has had a low of $0.41 and a high of $1.47. As of last week, the company has a debt-to-equity ratio of 1.76, a current ratio of 6.45, and a quick ratio of 6.14. The fifty day moving average price for NKTR is $0.8550 and a two-hundred day moving average price translates $0.6406 for the stock.
The latest earnings results from Nektar Therapeutics (NASDAQ: NKTR) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.22, missing analysts’ expectations of -$0.21 by -0.01. This compares to -$0.31 EPS in the same period last year. The net profit margin was -306.31% and return on equity was -110.95% for NKTR. The company reported revenue of $23.89 million for the quarter, compared to $22.02 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.45 percent. For the current quarter, analysts expect NKTR to generate $15.34M in revenue.
